Injecting viral peptides systemically into mice activated immune cells that then targeted pancreatic tumors, opening avenues to more accessible cancer therapy.
Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades. The findings could lead to a better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results